Akebia Therapeutics, Inc.AKBAEarnings & Financial Report
Nasdaq
NextMar 31, 2026
AKBA Q3 2025 Key Financial Metrics
Revenue
$58.8M
Gross Profit
$49.4M
Operating Profit
$4.4M
Net Profit
$540.0K
Gross Margin
84.0%
Operating Margin
7.6%
Net Margin
0.9%
YoY Growth
57.0%
EPS
$0.00
Financial Flow
Akebia Therapeutics, Inc. Q3 2025 Financial Summary
Akebia Therapeutics, Inc. reported revenue of $58.8M for Q3 2025, with a net profit of $540.0K (0.9% margin). Cost of goods sold was $9.4M, operating expenses totaled $44.9M.
Key Financial Metrics
| Total Revenue | $58.8M |
|---|---|
| Net Profit | $540.0K |
| Gross Margin | 84.0% |
| Operating Margin | 7.6% |
| Report Period | Q3 2025 |
Akebia Therapeutics, Inc. Annual Revenue by Year
Akebia Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $160.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $160.2M |
| 2023 | $194.6M |
| 2022 | $292.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.1M | $32.6M | $43.6M | $37.4M | $46.5M | $57.3M | $62.5M | $58.8M |
| YoY Growth | 1.6% | -18.7% | -22.6% | -11.0% | -17.1% | 75.8% | 43.1% | 57.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $241.7M | $225.5M | $220.2M | $207.1M | $220.7M | $310.2M | $345.6M | $364.2M |
| Liabilities | $272.3M | $252.7M | $253.9M | $257.5M | $269.9M | $285.6M | $316.4M | $322.6M |
| Equity | $-30.6M | $-27.3M | $-33.8M | $-50.4M | $-49.2M | $24.6M | $29.2M | $41.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-19.4M | $-10.1M | $-6.7M | $-4.5M | $-13.6M | $22.3M | $28.1M |